Waldenström's macroglobulinemia.

Current treatment options in oncology

Volumn 1, Issue 2, 2000, Pages 97-103

  Desikan, K Raman ^a   Dhodapkar, Madhav V ^a,b   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CHLORAMBUCIL; CLADRIBINE; DRUG DERIVATIVE; FLUDARABINE; MONOCLONAL ANTIBODY; RITUXIMAB; VIDARABINE;

BLOOD; CLINICAL TRIAL; HUMAN; MORTALITY; MULTIMODALITY CANCER THERAPY; PLASMAPHERESIS; REVIEW; SURVIVAL RATE; TUMOR RECURRENCE; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BETA 2-MICROGLOBULIN; CHLORAMBUCIL; CLADRIBINE; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; INTERFERON-ALPHA; NEOPLASM RECURRENCE, LOCAL; PLASMAPHERESIS; SURVIVAL RATE; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 0034211579     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-000-0054-5     Document Type: Review

References (50)

1. 1. FD Groves LB Travis SS Devesa 1998 Waldenström’s macroglobulinemia. Incidence patterns in the United States,1988-94. Cancer 82 1078 1081 9506352 10.1002/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3 1:STN:280:DyaK1c7msFWktw%3D%3D Groves FD, Travis LB, Devesa SS, et al.: Waldenström’s macroglobulinemia. Incidence patterns in the United States,1988-94. Cancer 1998, 82:1078–1081.
2. 2. EP Getaz WG Staples 1977 Familial Waldenström’s macroglobulinemia: a case report. S Afr Med J 51 891 892 408931 1:STN:280:DyaE2s3lvFaksg%3D%3D Getaz EP, Staples WG: Familial Waldenström’s macroglobulinemia: a case report. S Afr Med J 1977, 51:891–892.
3. 3. OG Bjornsson A Arnason P Gudmunsson 1978 Macroglobulinemia in an Icelandic family. Acta Med Scand 203 283 288 417561 1:STN:280:DyaE1c7mt1yqsg%3D%3D 10.1111/j.0954-6820.1978.tb14874.x Bjornsson OG, Arnason A, Gudmunsson P, et al.: Macroglobulinemia in an Icelandic family. Acta Med Scand 1978, 203:283–288.
4. 4. WA Blattner JE Garber DL Mann 1980 Waldenström’s macroglobulinemia and autoimmune disease in a family. Ann Intern Med 93 830 832 6778280 1:STN:280:DyaL3M%2FosVChsg%3D%3D Blattner WA, Garber JE, Mann DL, et al.: Waldenström’s macroglobulinemia and autoimmune disease in a family. Ann Intern Med 1980, 93:830–832.
5. 5. JM Fine JY Muller D Rochu 1986 Waldenström’s macroglobulinemia in monozygotic twins. Acta Med Scand 220 369 373 3099545 1:STN:280:DyaL2s%2Fps1GltA%3D%3D 10.1111/j.0954-6820.1986.tb02780.x Fine JM, Muller JY, Rochu D, et al.: Waldenström’s macroglobulinemia in monozygotic twins. Acta Med Scand 1986, 220:369–373.
6. 6. S Ahmed MS Shurafa CR Bishop M Varterasian 1999 Waldenström’s macroglobulinemia in young African American adults. Am J Hematol 60 229 230 10072116 10.1002/(SICI)1096-8652(199903)60:3<229::AID-AJH11>3.0.CO;2-L 1:STN:280:DyaK1M7ntVegsA%3D%3D Ahmed S, Shurafa MS, Bishop CR, Varterasian M: Waldenström’s macroglobulinemia in young African American adults. Am J Hematol 1999, 60:229–230.
7. 7. T Izumi R Sasaki S Tsunoda 1997 B-cell malignancy and hepatitis C virus infection. Leukemia 11 516 518 9209442 Izumi T, Sasaki R, Tsunoda S, et al.: B-cell malignancy and hepatitis C virus infection. Leukemia 1997, 11:516–518.
8. 8. MS Linet RL Humphrey ES Mehl 1993 A case-control and family study of Waldenström’s macroglobulinemia. Leukemia 7 1363 1369 8371587 1:STN:280:DyaK3szot1Witg%3D%3D Linet MS, Humphrey RL, Mehl ES, et al.: A case-control and family study of Waldenström’s macroglobulinemia. Leukemia 1993, 7:1363–1369.
9. 9. M Luppi Ferrari M Grazia G Bonaccorsi 1996 Hepatitis C virus infection in subset of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia 10 351 355 8637247 1:STN:280:DyaK283gtVWnuw%3D%3D Luppi M, Grazia Ferrari M, Bonaccorsi G, et al.: Hepatitis C virus infection in subset of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia 1996, 10:351–355.
10. 10. JL Tepper SV Feinman L D’Costa 1998 Hepatitis G and hepatitis C RNA virus coexisting in cryoglobulinemia. J Rheumatol 25 925 928 9598893 1:STN:280:DyaK1c3lvVynsg%3D%3D Tepper JL, Feinman SV, D’Costa L, et al.: Hepatitis G and hepatitis C RNA virus coexisting in cryoglobulinemia. J Rheumatol 1998, 25:925–928.
11. 11. P Brousset C Theirault D Roda 1998 Kaposi’s sarcoma-associated herpes virus (KSHV) in bone marrow biopsies of patients with Waldenström’s macroglobulinemia. Br J Haematol 102 795 797 9722309 10.1046/j.1365-2141.1998.00826.x 1:STN:280:DyaK1czoslOltg%3D%3D Brousset P, Theirault C, Roda D, et al.: Kaposi’s sarcoma-associated herpes virus (KSHV) in bone marrow biopsies of patients with Waldenström’s macroglobulinemia. Br J Haematol 1998, 102:795–797.
12. 12. F Agbalika X Mariette JP Marolleau 1998 Detection of human herpesvirus-8 in bone marrow biopsies from patients with multiple myeloma and Waldenström’s macroglobulinemia [letter]. Blood 91 4393 4393 9596693 1:CAS:528:DyaK1cXjsV2itb4%3D Agbalika F, Mariette X, Marolleau JP, et al.: Detection of human herpesvirus-8 in bone marrow biopsies from patients with multiple myeloma and Waldenström’s macroglobulinemia [letter]. Blood 1998, 91:4393.
13. 13. H Aoki M Takishita M Kosaka S Saito 1995 Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenström’s macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter’s syndrome but not in common CLL. Blood 85 1913 1919 7703494 1:CAS:528:DyaK2MXkslSjtbw%3D Aoki H, Takishita M, Kosaka M, Saito S: Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenström’s macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter’s syndrome but not in common CLL. Blood 1995, 85:1913–1919.
14. 14. Brouet JC: Immunobiology of Waldenström’s macroglobulinemia. 27th Congress of the International Society of Hematology Amsterdam, The Netherlands 1998, Educational Program Book, 44.
15. 15. E Matutes K Owusu-Ankomah R Morilla 1995 The immunological profile of B-cell disorders and proposal of scoring system for the diagnosis of CLL. Blood 85 1913 1913 Matutes E, Owusu-Ankomah K, Morilla R, et al.: The immunological profile of B-cell disorders and proposal of scoring system for the diagnosis of CLL. Blood 1995, 85:1913.
16. 16. Merlini G: Waldenström’s macroglobulinemia-clinical manifestations and prognosis. Hematology 1999, Educational Program of the American Society of Hematology, 358–369. Excellent review of biology.
17. 17. G Palka A Spadano L Geraci 1987 Chromosome changes in 19 patients with Waldenström’s macroglobulinemia. Cancer Genet Cytogenet 29 261 269 3119188 10.1016/0165-4608(87)90237-8 1:STN:280:DyaL1c%2Flt1GgtA%3D%3D Palka G, Spadano A, Geraci L, et al.: Chromosome changes in 19 patients with Waldenström’s macroglobulinemia. Cancer Genet Cytogenet 1987, 29:261–269.
18. 18. AD White RE Clark A Jacobs 1992 Isochromosome (6p) in Waldenström’s macroglobulinemia. Cancer Genet Cytogenet 58 89 91 1728957 10.1016/0165-4608(92)90141-T 1:STN:280:DyaK387gtlKhsg%3D%3D White AD, Clark RE, Jacobs A: Isochromosome (6p) in Waldenström’s macroglobulinemia. Cancer Genet Cytogenet 1992, 58:89–91.
19. 19. JC Cigudosa MJ Calasanz C Perez 1994 Complex karyotype including 14q+ marker in a case of Waldenström’s macroglobulinemia. Cancer Genet Cytogenet 73 169 170 8174094 10.1016/0165-4608(94)90204-6 1:STN:280:DyaK2c3ivVCrtg%3D%3D Cigudosa JC, Calasanz MJ, Perez C, et al.: Complex karyotype including 14q+ marker in a case of Waldenström’s macroglobulinemia. Cancer Genet Cytogenet 1994, 73:169–170.
20. 20. A Al-Katib R Mohammad M Hamdan 1993 Propagation of Waldenström’s macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. Blood 81 3034 3042 8499639 1:CAS:528:DyaK3sXkvVGgsro%3D Al-Katib A, Mohammad R, Hamdan M, et al.: Propagation of Waldenström’s macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. Blood 1993, 81:3034–3042.
21. 21. K Nishida M Taniwaki S Misawa T Abe 1989 Nonrandom rearrangement of chromosome 14 at band q 32.23 in human lymphoid malignancies with mature B-cell phenotype. Cancer Res 49 1275 1281 2492904 1:STN:280:DyaL1M7jsFyrtw%3D%3D Nishida K, Taniwaki M, Misawa S, Abe T: Nonrandom rearrangement of chromosome 14 at band q 32.23 in human lymphoid malignancies with mature B-cell phenotype. Cancer Res 1989, 49:1275–1281.
22. 22. Roman C San T Ferro M Guzman J Odriozola 1985 Clonal abnormalities in patients with Waldenström’s macroglobulinemia with special reference to Burkitt-type t(8:14). Cancer Genet Cytogenet 18 155 158 10.1016/0165-4608(85)90065-2 San Roman C, Ferro T, Guzman M, Odriozola J: Clonal abnormalities in patients with Waldenström’s macroglobulinemia with special reference to Burkitt-type t(8:14). Cancer Genet Cytogenet 1985, 18:155–158.
23. 23. K Offit NZ Parsa D Filippa 1992 t(9:14) (p13;q32) denotes a subset of low grade non-Hodgkin’s lymphoma with plasmacytoid differentiation. Blood 80 2594 2599 1384792 1:STN:280:DyaK3s%2FktlejtQ%3D%3D Offit K, Parsa NZ, Filippa D, et al.: t(9:14) (p13;q32) denotes a subset of low grade non-Hodgkin’s lymphoma with plasmacytoid differentiation. Blood 1992, 80:2594–2599.
24. 24. S Iida PH Rao P Nallasivam 1996 The t (9:14) (p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 88 4110 4117 8943844 1:STN:280:DyaK2s%2FpvFaltQ%3D%3D Iida S, Rao PH, Nallasivam P, et al.: The t (9:14) (p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 1996, 88:4110–4117.
25. 25. AH Ropper KC Gorson 1998 Neuropathies associated with paraproteinemia. N Engl J Med 338 1601 1607 9603799 10.1056/NEJM199805283382207 1:CAS:528:DyaK1cXjslGntr8%3D Ropper AH, Gorson KC: Neuropathies associated with paraproteinemia. N Engl J Med 1998, 338:1601–1607.
26. 26. MV Dhodapkar J Jacobson M Gertz 1999 Serum beta 2 microglobulin and IgM identify distinct prognostic subsets in patients with Waldenström’s macroglobulinemia. Blood 94 705a 705a Dhodapkar MV, Jacobson J, Gertz M, et al.: Serum beta 2 microglobulin and IgM identify distinct prognostic subsets in patients with Waldenström’s macroglobulinemia. Blood 1999, 94:705a.
27. 27. MA Dimopoulos R Alexanian 1994 Waldenström’s macroglobulinemia. Blood 83 1452 1459 8123836 1:STN:280:DyaK2c7mvFemtw%3D%3D Dimopoulos MA, Alexanian R: Waldenström’s macroglobulinemia. Blood 1994, 83:1452–1459.
28. 28. Dimpoulos MA: Waldenström’s macroglobulinemia-therapy. Hematology 1999, Education program of the American Society of Hematology, 370–375. Excellent review of therapy of WM.
29. 29. RA Kyle RP Greipp MA Gertz 1998 Waldenström’s macroglobulinemia: a prospective study comparing daily versus intermittent oral chlorambucil. Blood 92 279b 279b Kyle RA, Greipp RP, Gertz MA, et al.: Waldenström’s macroglobulinemia: a prospective study comparing daily versus intermittent oral chlorambucil. Blood 1998, 92:279b.
30. 30. Case DC Jr: Combination chemotherapy (M-2) protocol (BCNU, cyclophosphamide, melphalan and prednisone for Waldenström’s macroglobulinemia; preliminary report. Blood 1982, 59:934-937.
31. 31. DC Case TJ Ervin MA Boyd DL Redfield 1992 Waldenström’s macroglobulinemia: long-term results with M-2 protocol. Cancer Invest 9 1 7 Case DC Jr, Ervin TJ, Boyd MA, Redfield DL: Waldenström’s macroglobulinemia: long-term results with M-2 protocol. Cancer Invest 1992, 9:1–7.
32. 32. MA Dimpoulos H Kantarjian D Weber 1994 Primary therapy of Waldenström’s macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12 2694 2698 Dimpoulos MA, Kantarjian H, Weber D, et al.: Primary therapy of Waldenström’s macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994, 12:2694–2698.
33. 33. MA Fridrik G Jager C Baldinger 1997 First-line treatment of Waldenström’s disease with cladribine. Ann Hematol 74 7 10 9031608 10.1007/s002770050247 1:STN:280:DyaK2s7otlKnsA%3D%3D Fridrik MA, Jager G, Baldinger C, et al.: First-line treatment of Waldenström’s disease with cladribine. Ann Hematol 1997, 74:7–10.
34. 34. A Hellmann K Lewandowski JM Zancha 1999 Treatment of Waldenström’s macroglobulinemia with 2-chlordeoxyadenosine. Eur J Haematol 63 35 41 10414453 1:CAS:528:DyaK1MXksVaju70%3D 10.1111/j.1600-0609.1999.tb01848.x Hellmann A, Lewandowski K, Zancha JM, et al.: Treatment of Waldenström’s macroglobulinemia with 2-chlordeoxyadenosine. Eur J Haematol 1999, 63:35–41.
35. 35. JM Foran AZ Rohatiner B Coiffier 1999 Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström’s macroglobulinemia and mantle cell lymphoma. J Clin Oncol 17 546 553 10080598 1:CAS:528:DyaK1MXht1Wmurc%3D Foran JM, Rohatiner AZ, Coiffier B, et al.: Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström’s macroglobulinemia and mantle cell lymphoma. J Clin Oncol 1999, 17:546–553.
36. 36. M Dhodapkar J Jacobson M Gertz 1997 Phase II intergroup trial of fludarabine in Waldenström’s macroglobulinemia: results of a Southwest Oncology Group trial 9003 in 220 patients. Blood 90 577a 577a Dhodapkar M, Jacobson J, Gertz M, et al.: Phase II intergroup trial of fludarabine in Waldenström’s macroglobulinemia: results of a Southwest Oncology Group trial 9003 in 220 patients. Blood 1997, 90:577a.
37. 37. MA Dimopoulos S O’Brien H Kantarjian 1993 Fludarabine therapy in Waldenström’s macroglobulinemia. Am J Med 95 49 52 8328496 10.1016/0002-9343(93)90231-D 1:STN:280:DyaK3szhvVyqtw%3D%3D Dimopoulos MA, O’Brien S, Kantarjian H, et al.: Fludarabine therapy in Waldenström’s macroglobulinemia. Am J Med 1993, 95:49–52.
38. 38. PL Zinzani F Gherlinzoni M Bendandi 1995 Fludarabine treatment in resistant Waldenström’s macroglobulinemia. Eur J Haematol 54 120 123 7698295 1:STN:280:DyaK2M3ht1GitQ%3D%3D 10.1111/j.1600-0609.1995.tb01779.x Zinzani PL, Gherlinzoni F, Bendandi M, et al.: Fludarabine treatment in resistant Waldenström’s macroglobulinemia. Eur J Haematol 1995, 54:120–123.
39. 39. V Leblond T Ben-Othman E Deconinck 1998 Activity of fludarabine in previously treated Waldenström’s macroglobulinemia: a report of 71 cases. Group Coperatif Macroglobulinemie. J Clin Oncol 16 2060 2064 9626204 1:STN:280:DyaK1c3ovFCntg%3D%3D Leblond V, Ben-Othman T, Deconinck E, et al.: Activity of fludarabine in previously treated Waldenström’s macroglobulinemia: a report of 71 cases. Group Coperatif Macroglobulinemie. J Clin Oncol 1998, 16:2060–2064.
40. 40. MA Dimopoulos D Weber KB Dellasalle 1995 Treatment of Waldenström’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 6 49 52 7710983 1:STN:280:DyaK2M3is1ensQ%3D%3D Dimopoulos MA, Weber D, Dellasalle KB, et al.: Treatment of Waldenström’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 1995, 6:49–52.
41. 41. V Leblond B Cazin JP Fermand 1999 Results of a multicentric randomized study comparing the efficacy of fludarabine (FAMP) to that of cyclophosphamide, doxorubicin and prednisone (CAP) in patients in first relapse or primary refractory disease with Waldenström’s macroglobulinemia. Blood 94 704a 704a Leblond V, Cazin B, Fermand JP, et al.: Results of a multicentric randomized study comparing the efficacy of fludarabine (FAMP) to that of cyclophosphamide, doxorubicin and prednisone (CAP) in patients in first relapse or primary refractory disease with Waldenström’s macroglobulinemia. Blood 1999, 94:704a.
42. 42. MA Dimpoulos DM Weber H Kantarjian 1994 2-chlorodeoxyadenosine therapy of patients with Waldenström’s macroglobulinemia previously treated with fludarabine. Ann Oncol 5 288 289 Dimpoulos MA, Weber DM, Kantarjian H, et al.: 2-chlorodeoxyadenosine therapy of patients with Waldenström’s macroglobulinemia previously treated with fludarabine. Ann Oncol 1994, 5:288–289.
43. 43. G DeRosa A DeRenzo S Buffordi B Rotoloi 1989 Treatment of Waldenström’s macroglobulinemia with interferon. Haematologica 74 313 315 1:STN:280:DyaK3c%2FmtV2rsA%3D%3D DeRosa G, DeRenzo A, Buffordi S, Rotoloi B: Treatment of Waldenström’s macroglobulinemia with interferon. Haematologica 1989, 74:313–315.
44. 44. B Rotoli A DeRenzo F Frigeri 1995 A phase II trial on alpha-interferon effect in monoclonal IgM gammopathy. Leuk Lymphoma 19 337 342 Rotoli B, DeRenzo A, Frigeri F, et al.: A phase II trial on alpha-interferon effect in monoclonal IgM gammopathy. Leuk Lymphoma 1995, 19:337–342.
45. 45. E Legouffe JF Rossi JP Laporte 1995 Treatment of Waldenström’s macroglobulinemia with very low doses of alpha interferon. Leuk Lymphoma 19 337 342 8535228 1:STN:280:DyaK287hs12itQ%3D%3D Legouffe E, Rossi JF, Laporte JP, et al.: Treatment of Waldenström’s macroglobulinemia with very low doses of alpha interferon. Leuk Lymphoma 1995, 19:337–342.
46. 46. JC Byrd CA White B Link 1998 Rituximab therapy in previously treated Waldenström’s macroglobulinemia: preliminary evidence of activity. Blood 92 106a 106a Byrd JC, White CA, Link B, et al.: Rituximab therapy in previously treated Waldenström’s macroglobulinemia: preliminary evidence of activity. Blood 1998, 92:106a.
47. 47. JM Foran AZ Rohatiner D Cunningham 1998 Immunotherapy of mantle cell lymphoma, lymphoplasmacytoid lymphoma, Waldenström’s macroglobulinemia and small lymphocytic lymphoma with Rituximab [abstract]. Br J Haematol 102 149 149 Foran JM, Rohatiner AZ, Cunningham D, et al.: Immunotherapy of mantle cell lymphoma, lymphoplasmacytoid lymphoma, Waldenström’s macroglobulinemia and small lymphocytic lymphoma with Rituximab [abstract]. Br J Haematol 1998, 102:149.
48. 48. R Desikan M Dhodapkar D Siegel 1999 High-dose therapy with autologous haemopoietic stem cell support for Waldenström’s macroglobulinemia. Br J Haematol 105 993 996 10554812 10.1046/j.1365-2141.1999.01461.x 1:STN:280:DC%2BD3c%2FitFarsQ%3D%3D Pilot trials of high-dose therapy of WM Desikan R, Dhodapkar M, Siegel D, et al.: High-dose therapy with autologous haemopoietic stem cell support for Waldenström’s macroglobulinemia. Br J Haematol 1999, 105:993–996.Pilot trials of high-dose therapy of WM
49. 49. P Dreger B Glass R Kuse 1999 Myeloablative therapy followed by reinfusion of purged autologous stem cells for Waldenström’s macroglobulinemia Br J Haematol 106 115 118 10444173 10.1046/j.1365-2141.1999.01493.x 1:STN:280:DyaK1MzntlGmtQ%3D%3D Dreger P, Glass B, Kuse R, et al.: Myeloablative therapy followed by reinfusion of purged autologous stem cells for Waldenström’s macroglobulinemia. Br J Haematol 1999, 106:115–118.
50. 50. B Barlogie S Jagannath KR Desikan 1999 Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 93 55 65 9864146 1:STN:280:DyaK1M%2FotFKjsA%3D%3D Barlogie B, Jagannath S, Desikan KR, et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999, 93:55–65.